20 Apr 2022 |
BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
|
20 Apr 2022 |
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
|
19 Apr 2022 |
Enhertu granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
|
19 Apr 2022 |
Amgen announces positive top-line results from phase 3 study of ABP 654, biosimilar candidate to Stelara (ustekinumab)
|
19 Apr 2022 |
Biocytogen Enters Agreement With CtM Bio to Co-develop TCR-Mimic Antibody-Based Multi-Specific T cell Engagers
|
18 Apr 2022 |
Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
|
15 Apr 2022 |
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
|
15 Apr 2022 |
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
|
15 Apr 2022 |
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
|
14 Apr 2022 |
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease
|
14 Apr 2022 |
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)
|
14 Apr 2022 |
Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines
|
14 Apr 2022 |
Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
|
14 Apr 2022 |
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
|
14 Apr 2022 |
Ubix Therapeutics, SK Biopharmaceuticals enter into research collaboration agreement to develop novel therapeutics based on targeted protein degradation
|
14 Apr 2022 |
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
|
14 Apr 2022 |
CDR-Life Announces $76 Million Raised in Series A Funding
|
13 Apr 2022 |
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
|
13 Apr 2022 |
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
|
13 Apr 2022 |
Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022
|